Cancer Channel
Related Channels

Revlimid Dangers and Infants

Taking Revlimid® (lenalidomide) during pregnancy can cause severe birth defects and even death in an unborn infant. Because of these dangers, Revlimid is classified as a pregnancy Category X medication, which means the potential risks clearly outweigh the potential benefits of this medicine.
A woman of childbearing potential must have two negative pregnancy tests before starting treatment with Revlimid. Once treatment is started, pregnancy tests will be given throughout treatment.
If you are a woman of childbearing potential, you must agree to use two forms of birth control for at least four weeks before starting Revlimid, while taking the medication, and for at least four weeks after your last dose.
In addition, Revlimid is found in semen. Therefore, men taking the medication must agree to use a latex condom during sex with a woman of childbearing potential throughout treatment, and for at least four weeks after treatment ends.
(For more details, click Revlimid and Pregnancy. This Web page presents more information on the potentially dangerous complications that could occur if this drug is given to a pregnant woman.)
The Zen of Cancer Caregiving - Recharge Your Batteries!
Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.